These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1040 related articles for article (PubMed ID: 29650362)

  • 1. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
    Italiano A; Soria JC; Toulmonde M; Michot JM; Lucchesi C; Varga A; Coindre JM; Blakemore SJ; Clawson A; Suttle B; McDonald AA; Woodruff M; Ribich S; Hedrick E; Keilhack H; Thomson B; Owa T; Copeland RA; Ho PTC; Ribrag V
    Lancet Oncol; 2018 May; 19(5):649-659. PubMed ID: 29650362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.
    Morschhauser F; Tilly H; Chaidos A; McKay P; Phillips T; Assouline S; Batlevi CL; Campbell P; Ribrag V; Damaj GL; Dickinson M; Jurczak W; Kazmierczak M; Opat S; Radford J; Schmitt A; Yang J; Whalen J; Agarwal S; Adib D; Salles G
    Lancet Oncol; 2020 Nov; 21(11):1433-1442. PubMed ID: 33035457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.
    Gounder M; Schöffski P; Jones RL; Agulnik M; Cote GM; Villalobos VM; Attia S; Chugh R; Chen TW; Jahan T; Loggers ET; Gupta A; Italiano A; Demetri GD; Ratan R; Davis LE; Mir O; Dileo P; Van Tine BA; Pressey JG; Lingaraj T; Rajarethinam A; Sierra L; Agarwal S; Stacchiotti S
    Lancet Oncol; 2020 Nov; 21(11):1423-1432. PubMed ID: 33035459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.
    Munakata W; Shirasugi Y; Tobinai K; Onizuka M; Makita S; Suzuki R; Maruyama D; Kawai H; Izutsu K; Nakanishi T; Shiba S; Hojo S; Ando K
    Cancer Sci; 2021 Mar; 112(3):1123-1131. PubMed ID: 33492746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan.
    Izutsu K; Ando K; Nishikori M; Shibayama H; Teshima T; Kuroda J; Kato K; Imaizumi Y; Nosaka K; Sakai R; Hojo S; Nakanishi T; Rai S
    Cancer Sci; 2021 Sep; 112(9):3627-3635. PubMed ID: 34159682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study.
    Zauderer MG; Szlosarek PW; Le Moulec S; Popat S; Taylor P; Planchard D; Scherpereel A; Koczywas M; Forster M; Cameron RB; Peikert T; Argon EK; Michaud NR; Szanto A; Yang J; Chen Y; Kansra V; Agarwal S; Fennell DA
    Lancet Oncol; 2022 Jun; 23(6):758-767. PubMed ID: 35588752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial.
    Song Y; Liu Y; Li ZM; Li L; Su H; Jin Z; Zuo X; Wu J; Zhou H; Li K; He C; Zhou J; Qi J; Hao S; Cai Z; Li Y; Wang W; Zhang X; Zou J; Zhu J
    Lancet Haematol; 2022 Jul; 9(7):e493-e503. PubMed ID: 35772429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
    Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
    Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
    Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
    Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
    Nastoupil LJ; Lunning MA; Vose JM; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Burger JA; Wierda WG; O'Brien S; Sportelli P; Miskin HP; Purdom MA; Weiss MS; Fowler NH
    Lancet Haematol; 2019 Feb; 6(2):e100-e109. PubMed ID: 30709431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
    Michot JM; Bouabdallah R; Vitolo U; Doorduijn JK; Salles G; Chiappella A; Zinzani PL; Bijou F; Kersten MJ; Sarmiento R; Mosulen S; Mendez C; Uttamsingh S; Pourdehnad M; Hege K; Chen T; Klein C; Hagner PR; Nikolova Z; Ribrag V
    Lancet Haematol; 2020 Sep; 7(9):e649-e659. PubMed ID: 32758434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
    Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
    Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
    Bannerji R; Arnason JE; Advani RH; Brown JR; Allan JN; Ansell SM; Barnes JA; O'Brien SM; Chávez JC; Duell J; Rosenwald A; Crombie JL; Ufkin M; Li J; Zhu M; Ambati SR; Chaudhry A; Lowy I; Topp MS
    Lancet Haematol; 2022 May; 9(5):e327-e339. PubMed ID: 35366963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors.
    Yap TA; Winter JN; Giulino-Roth L; Longley J; Lopez J; Michot JM; Leonard JP; Ribrag V; McCabe MT; Creasy CL; Stern M; Pene Dumitrescu T; Wang X; Frey S; Carver J; Horner T; Oh C; Khaled A; Dhar A; Johnson PWM
    Clin Cancer Res; 2019 Dec; 25(24):7331-7339. PubMed ID: 31471312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
    Davis KL; Fox E; Merchant MS; Reid JM; Kudgus RA; Liu X; Minard CG; Voss S; Berg SL; Weigel BJ; Mackall CL
    Lancet Oncol; 2020 Apr; 21(4):541-550. PubMed ID: 32192573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
    Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
    Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
    Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
    Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.